

Title (en)  
MODULATION OF IMMUNE RESPONSE BY RIBAVIRIN

Title (de)  
MODULIERUNG DER IMMUNREAKTION DURCH RIBAVIRIN

Title (fr)  
MODULATION DE REPONSE IMMUNITAIRE PAR LA RIBAVIRINE

Publication  
**EP 1146883 A4 20041124 (EN)**

Application  
**EP 99968159 A 19991220**

Priority  
• US 9930490 W 19991220  
• US 24136799 A 19990129

Abstract (en)  
[origin: WO0044388A1] The response of an immune system to a challenge is modified by presenting the system with a nucleoside in a concentration selected to have an effect on a B7 marker that is inverse from the effect of the challenge. Contemplated challenges include allergens, neoplasm, virus, bacteria, infestation, and autoimmune reaction. Molecular markers of particular interest are B7-1 and B7-2. Preferred nucleosides are Ribavirin and Ribavirin analogs, especially provided within a concentration range between about 0.2 :M and about 5 :M, respectively, in a fluid containing cells expressing the B7 marker.

IPC 1-7  
**A61K 31/70**; **C07H 19/052**

IPC 8 full level  
**A61K 31/00** (2006.01); **A61K 31/7052** (2006.01); **A61K 31/7084** (2006.01); **A61P 1/00** (2006.01); **A61P 1/16** (2006.01); **A61P 3/10** (2006.01); **A61P 11/06** (2006.01); **A61P 15/00** (2006.01); **A61P 17/06** (2006.01); **A61P 19/02** (2006.01); **A61P 21/00** (2006.01); **A61P 29/00** (2006.01); **A61P 31/04** (2006.01); **A61P 31/12** (2006.01); **A61P 31/18** (2006.01); **A61P 37/00** (2006.01); **A61P 37/02** (2006.01); **A61P 37/06** (2006.01); **A61P 37/08** (2006.01)

CPC (source: EP KR)  
**A61K 31/00** (2013.01 - EP); **A61K 31/7056** (2013.01 - KR); **A61P 1/00** (2018.01 - EP); **A61P 1/16** (2018.01 - EP); **A61P 3/10** (2018.01 - EP); **A61P 11/06** (2018.01 - EP); **A61P 15/00** (2018.01 - EP); **A61P 17/06** (2018.01 - EP); **A61P 19/02** (2018.01 - EP); **A61P 21/00** (2018.01 - EP); **A61P 29/00** (2018.01 - EP); **A61P 31/04** (2018.01 - EP); **A61P 31/12** (2018.01 - EP); **A61P 31/18** (2018.01 - EP); **A61P 37/00** (2018.01 - EP); **A61P 37/02** (2018.01 - EP); **A61P 37/06** (2018.01 - EP); **A61P 37/08** (2018.01 - EP)

Citation (search report)  
• [X] WO 9726883 A1 19970731 - ICN PHARMACEUTICALS [US], et al  
• [X] EP 0383361 A2 19900822 - VIRA TEK INC [US]  
• [X] US 5030623 A 19910709 - GRUBER HARRY E [US]  
• [X] EP 0643970 A2 19950322 - VIRA TEK INC [US]  
• [X] EP 0038629 A1 19811028 - BEECHAM GROUP PLC [GB]  
• [X] US 4211771 A 19800708 - ROBINS RONALD K [US], et al  
• [X] WO 8705807 A1 19871008 - GRUBER HARRY EDWARD  
• See also references of WO 0044388A1

Designated contracting state (EPC)  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)  
**WO 0044388 A1 20000803**; AU 2483300 A 20000818; BR 9917090 A 20011016; CA 2357735 A1 20000803; CN 1334736 A 20020206; CZ 20012519 A3 20020515; EP 1146883 A1 20011024; EP 1146883 A4 20041124; HK 1040937 A1 20020628; HR P20010496 A2 20030831; HU P0200027 A2 20020429; IL 144130 A0 20020523; JP 2002535371 A 20021022; KR 20020023939 A 20020329; MX PA01007211 A 20020506; NO 20013529 D0 20010717; NO 20013529 L 20010912; PL 364699 A1 20041213; RU 2211698 C2 20030910; SI 20802 A 20020831; SK 10092001 A3 20020205; ZA 200105595 B 20021007

DOCDB simple family (application)  
**US 9930490 W 19991220**; AU 2483300 A 19991220; BR 9917090 A 19991220; CA 2357735 A 19991220; CN 99815897 A 19991220; CZ 20012519 A 19991220; EP 99968159 A 19991220; HK 02102923 A 20020418; HR P20010496 A 20010702; HU P0200027 A 19991220; IL 14413099 A 19991220; JP 2000595690 A 19991220; KR 20017009609 A 20010730; MX PA01007211 A 19991220; NO 20013529 A 20010717; PL 36469999 A 19991220; RU 2001119056 A 19991220; SI 9920099 A 19991220; SK 10092001 A 19991220; ZA 200105595 A 20010706